Results 41 to 50 of about 7,625 (228)

Emerging Bismuth Chalcogenides Based Nanodrugs for Cancer Radiotherapy

open access: yesFrontiers in Pharmacology, 2022
Radiotherapy (RT), as one of the main methods of clinical tumor treatment, has been applied to the treatment of most solid tumors. However, the effect of RT is compromised by the radiation resistance of tumor hypoxic environment and non-specific damage ...
Jia Huang   +9 more
doaj   +1 more source

An Activity‐Reinforced P‐Modified Single‐Atom Cu Nanozyme Potentiates IDO Blockade‐Induced Tumor Radiotherapy

open access: yesAdvanced Science, EarlyView.
A phosphorus‐modified single‐atom copper nanozyme delivering the IDO1 inhibitor 1‐methyl‐tryptophan enhances breast cancer radioimmunotherapy by simultaneously relieving hypoxia and inducing immunogenic cell death through dual enzyme activities while blocking tryptophan metabolism to suppress regulatory T cell function.
Wei Zhao   +11 more
wiley   +1 more source

Radiosensitizers in cervical cancer. Cisplatin and beyond [PDF]

open access: yes, 2006
Cervical cancer continues to be a significant health burden worldwide. Globally, the majority of cancers are locally advanced at diagnosis; hence, radiation remains the most frequently used therapeutical modality. Currently, the value of adding cisplatin
Garcia-Arias, Alicia   +11 more
core   +1 more source

Understanding the molecular mechanism responsible for developing therapeutic radiation-induced radioresistance of rectal cancer and improving the clinical outcomes of radiotherapy - A review

open access: yesCancer Biology & Therapy
Rectal cancer accounts for the second highest cancer-related mortality, which is predominant in Western civilizations. The treatment for rectal cancers includes surgery, radiotherapy, chemotherapy, and immunotherapy.
Samatha M Jain   +8 more
doaj   +1 more source

An Injectable Metal‐Drug Supramolecular Condensate Enables Radiosensitization and Systemic Antitumor Immunity for Post‐Surgical Osteosarcoma Therapy

open access: yesAdvanced Science, EarlyView.
This work designed an injectable metal‐drug supramolecular condensate formed from hafnium ions and alendronate (Hf‐ALN) and loaded with the COX‐2 inhibitor celecoxib (CXB) for synergistic radioimmunotherapy of postoperative osteosarcoma. Mechanistically, upon X‐ray irradiation, Hf enhances radiation energy deposition, ROS generation, and DNA damage ...
Tianhua Xiao   +12 more
wiley   +1 more source

Radiosensitization: Studies and Modern Approaches to Cellular Radiosensitivity

open access: yesInternational Journal of Biomedicine, 2023
Even though radiation therapy has achieved great success, there is still an unsolved task of increasing radiation damage to tumor tissue and reducing side effects on healthy tissues. There is a wide variety of obstacles that reduce the efficiency of radiotherapy.
openaire   +2 more sources

Multifunctional Nanovaccine‐Radiotherapy Synergy Drives Anti‐Tumor Immunity via Multi‐Cascade Cell Death for Pancreatic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Machine‐learning‐driven transcriptomic analysis identifies FSTL3 as a key tumor‐microenvironment regulator in desmoplastic pancreatic adenocarcinoma. A cRGD‐modified liposome co‐loading gemcitabine and siFSTL3 serves as an irradiation‐triggered in situ nanovaccine. It synergizes with radiotherapy to induce ferroptosis and immunogenic cell death through
Chengyi Huang   +11 more
wiley   +1 more source

Hydration and Radiosensitivity

open access: yesExperimental Biology and Medicine, 1955
Summary and Conclusions1. Artemia “eggs,” essentially in the blastula stage in suspended development, can tolerate about 200,- 000 r more x-radiation in the dry than in the wet state, if criteria of hatching and motility after 48 hours hydration are considered. 2.
R, RUGH, H, CLUGSTON
openaire   +2 more sources

DDX21 Enhances Radiosensitivity in Head and Neck Squamous Cell Carcinoma by Suppressing MK2‐Mediated DNA Damage Response

open access: yesAdvanced Science, EarlyView.
DDX21 suppresses MK2 activation by directly inhibiting Thr334 phosphorylation in a p38‐independent manner, thereby impairing DNA damage response. Clinically, patients with well‐differentiated tumors exhibiting high DDX21 expression are more likely to benefit from adjuvant radiotherapy, whereas those with low DDX21 levels are predisposed to ...
Tianru Yang   +8 more
wiley   +1 more source

Combination of radiosensitizers and hyperthermia in tumour radiotherapy [PDF]

open access: yes, 1981
ReviewSpecific metabolic properties of hypoxic (and therefore radio-resistant) tumour cells are responsible for the selective effect of radiosensitizers (such as misonidazole) and hyperthermia upon these cells in respect of radiosensitization as well as ...
Brueckner, V.
core  

Home - About - Disclaimer - Privacy